ACAMPROSATE AND RELAPSE PREVENTION IN THE TREATMENT OF ALCOHOL DEPENDENCE: A PLACEBO-CONTROLLED STUDY
The DOI matches its Crossref record.
Abstract
The objective of this study was to compare acamprosate with placebo in the treatment of alcohol-dependent patients during a 6-month post-detoxification treatment and a 3-month medication-free follow-up. Patients (n = 330) were detoxified and randomized to treatment with acamprosate (1998 mg/day) or placebo within an out-patient programme including medical counselling, psychotherapy and self-help groups. The main outcome criterion was drinking behaviour as assessed by: abstinence/relapse ratio, cumulative abstinence duration (CAD) and the period of continued abstinence. Anxiety, depression and craving were also monitored. Intention to treat (ITT) statistical principles were followed. Twenty-five per cent of patients dropped out over the first 6 months. At the end of the treatment period, the abstinence rate was 57.9% for acamprosate and 45.2% for placebo (P = 0.03). The CAD was 110+/-77 days for acamprosate and 89+/-77 days for placebo (P = 0.016). Patients on acamprosate had a higher continuous abstinence rate and experienced less severe relapses. No differential effect was noted for anxiety, depression or craving. Treatment remained positive, but not significant, 3 months after termination of study medication. No significant difference in adverse events was noted between treatment groups. Acamprosate treatment over 180 days was consistently more effective than placebo to maintain abstinence and to diminish relapse severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Room, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure
Epstein, D. H., Preston, K. L., Stewart, J., & Shaham, Y. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0529-6 · Cited by 620
Carmen, B., Angeles, M., Ana, M., & María, A. J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00763.x · Cited by 504
Substance Abuse Among Older Adults
Kuerbis, A., Sacco, P., Blazer, D. G., & Moore, A. A. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.008 · Cited by 505
“Acamprosate is an NMDA and GABA receptor modulator used to reduce craving and the pleasant effects of alcohol.(123,125) No trials have been conducted to examine the efficacy of acamprosate for individuals aged 65 years and older.”
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400
Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390
Mann, K., Lehert, P., & Morgan, M. Y. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000108656.81563.05 · Cited by 364
Rösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
Conceptualizing changes in behavior in intervention research: the range of possible changes model
De Los Reyes, A., & Kazdin, A. E. (2006) · Psychological Review · doi:10.1037/0033-295x.113.3.554 · Cited by 172
Conceptual framework for the etiology of alcoholism: a “kindling”/stress hypothesis
Breese, G. R., Overstreet, D. H., & Knapp, D. J. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2016-2 · Cited by 167
A quantitative review of the ubiquitous relapse curve
Kirshenbaum, A. P., Olsen, D. M., & Bickel, W. K. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2008.04.001 · Cited by 125
Relapse Prevention and Maintaining Abstinence in Older Adults with Alcohol-Use Disorders
Barrick, C., & Connors, G. J. (2002) · Drugs & Aging · doi:10.2165/00002512-200219080-00004 · Cited by 126
Mason, B. J. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.009 · Cited by 75
Acamprosate: a review of its use in alcohol dependence
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0423-9 · Cited by 65
“Primary outcomes were significantly better with acamprosate than placebo in several other short- to medium-term studies, including the mean cumulative abstinence duration in a smaller (n = 188) 3-month trial [35] and in various larger (n = 262–330) 6-month studies [31, 32, 37], as well as complete abstinence rates in…”
BackgroundPsychological interventions for co-occurring depression and substance use disorders
Hides, L., Quinn, C., Stoyanov, S., Kavanagh, D., & Baker, A. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009501.pub2 · Cited by 32
Ng, S.-M., Rentala, S., Chan, C. L. W., & Nayak, R. B. (2020) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000368 · Cited by 12
“ns INTRODUCTION Alcohol dependence is not only a form of chronic central nervous system disorder but also one of the most severe public health issues globally (Sinha & Dharmadhikari, 2015), characterized by craving, tolerance, a preoccupation with alcohol, and continued drinking despite harmful consequences (Miller &…”
BackgroundSubstance‐Related Disorders: Alcohol‐Related Disorders
Babor, T. F., Hernandez‐Avila, C. A., & Ungemack, J. A. (2015) · Psychiatry · doi:10.1002/9781118753378.ch72 · Cited by 8
Metadata
- Authors
- Tempesta, E.
- Venue
- Alcohol and Alcoholism
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-01
- Volume
- 35
- Issue
- 2
- Pages
- 202-209
- ISSN
- 0735-0414 (ISSN-L)
- 1464-3502
- OpenAlex
- W2095902274
- Cited by
- 155
- References
- 0
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.